Healthcare
Live Price
Offline$4.82
+1.90% today
1Y Change
+141.89%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Precigen, Inc. (PGEN) is a Healthcare stock with a market cap of $1.23B and listed on NASDAQ. The stock last traded around $4.82 and up 141.9% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of +146.7%, EPS growth of -200.0%, a dividend yield of 0.0%. What stands out right now is revenue +146.7%, EPS -200.0%, free cash flow -17.0% with operating margin -1141.1% and ROIC -91.7%. Valuation already assumes a fairly strong business story at price/sales 126.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PGEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PGEN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PGEN Max Drawdown
-40.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PGEN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$9.7M
+146.7% YoY
FY Net Income
-$250.6M
-98.6% YoY
Free Cash Flow
-$89.8M
-17.0% YoY
Revenue Growth
+146.7%
EPS Growth
-200.0%
Gross Margin
42.1%
Net Margin
-2588.2%
Income statement
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 14M | 27M | 6M | 4M | 10M |
| Gross Profit | 9M | 21M | 106K | -342K | 5M |
| Operating Income | -91M | -75M | -89M | -95M | -107M |
| EBITDA | -78M | -61M | -78M | -83M | -100M |
| Net Income | -92M | 28M | -96M | -126M | -251M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36M | 5M | 8M | 30M | 30M |
| Total Assets | 360M | 216M | 151M | 145M | 156M |
| Total Liabilities | 253M | 90M | 33M | 107M | 135M |
| Shareholder Equity | — | — | — | — | — |
| Total Debt | 190M | 51M | 7M | 6M | 98M |
| Net Debt | — | — | — | — | — |
Cash flow positioning
2026 Full Year
Operating Cash Flow
236M
-115.0% YoY
Capital Expenditures
—
Free Cash Flow
90M
-17.0% YoY
Key ratios
Gross Margin
42.1%
Operating Margin
-1141.1%
Net Margin
-2588.2%
ROE
-8396.7%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.